Patents expiring between 2025-2030 will put more than $200 billion of Big Pharma’s revenues at risk, thus positioning them to fill their pipelines through acquisitions.
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
